Good news, China's first COVID-19 specific medicine has arrived. According to the People's Daily, on February 9th, 65438, Tsinghua University released the research and development results of anti-COVID-19 specific drugs. The combination therapy of monoclonal neutralizing antibody, Ambavirmonoclonal antibody and romise monoclonal antibody developed by Professor Zhang of Tsinghua University Medical College was approved by China. It means that China has the first COVID-19 specific drug, which can provide treatment and prevention. Vaccine and antibody drugs have a good complementary effect, and one injection can last for 9 months or even a year.

As we all know, the original intention of vaccine is prevention, while medicine is treatment. Then you need to know a few questions about specific drugs.

Applicable population of specific drugs

Mild and ordinary adults with high risk factors for developing serious diseases (including hospitalization or death).

Adolescents infected in COVID-19 (12- 17 years old, weight ≥40kg), among which the indications for adolescents are conditionally approved.

There are also some infected people with basic diseases, such as obesity, cardiovascular disease, diabetes, etc., which are also applicable.

The main function is treatment. The antibody can remain in the human body for 9 ~ 12 months, which can not only play a preventive role, but also play a therapeutic role.